Urinary Interleukin 6: A Prognostic Bio Marker in Lupus Nephritis

Urinary Interleukin 6: A Prognostic Bio Marker in Lupus Nephritis

  • Vijay Pratap Singh Consultant nephrologists Gorakhpur, Uttar Pradesh, India
  • Deba Prasad Kar Department of Nephrology, IMS and SUM hospital, Siksha “O” Anusandhan University (Deemed to be), K8, Kalinga nagar, Bhubaneswar-751003, Odisha, India
  • Bandita Dash Department of health centre, National Institute of Science Education and Research, Bhubaneswar, Khurda 752050, Odisha, India
  • Jatindra Nath Mohanty Medical Research Laboratory, IMS and SUM hospital, Siksha “O” Anusandhan University (Deemed to be), K8, Kalinga nagar,Bhubaneswar-751003, Odisha, India
Keywords: Urinary IL-6, Lupus nephritis, Bio marker, Urinary protein

Abstract

Background: Lupus nephritis is an frequent and potentially serious complication of SLE. It is an inflammatory disease of connective tissue and immune system, where we find organs and cells undergo damage initially mediated by  tissue-restricting  auto antibodies and immune complexes. Our aim was to evaluate the  association of urinary interleukin 6 in lupus nephritis patients and validate its use as a prognostic marker.  For this we took the complete demographic profiling of the participant patients along with all biochemical parameter were checked. For IL-6 analysis, we analyzed the whole immunological profile and correlated the level of urinary proteins, serum creatinine and urinary IL-6. The mean values of urinary IL-6 at presentation and after 6 months of treatment were calculated. Any change after 6 months was noted and correlation of Il-6 with disease activity scores was observed. Urinary IL-6 was found to be significantly high in patients of lupus nephritis than controls. Urinary IL-6 was higher in patients of severe form of lupus nephritis such as Class IV than other classes of lupus nephritis. Urinary IL-6 may be used as a prognostic marker of lupus nephritis. The patients who achieved complete remission had near normal levels of urinary IL-6 and patients with partial remission had decreased level of urinary IL-6 than at presentation  after 6 months of induction phase treatment. But patients with no remission did not show any significant decrease in urinary IL-6 levels at 6 months. So, urinary Il-6 may be used to monitor the response to therapy.

Published
2019-11-27